Home   >  
Angiogenesis/Protein Tyrosine Kinase

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
N-Desethyl Sunitinib Chemical Structure
BCP20914 N-Desethyl Sunitinib 356068-97-8
N-Desethyl Sunitinib is a metabolite of sunitinib.
JNJ-10198409 Chemical Structure
BCP08276 JNJ-10198409 627518-40-5
JNJ-10198409, also known as RWJ-540973, is an inhibitor of PDGF-BB tyrosine kinase with an IC50 value of 4.2 nM.
SU 4312 Chemical Structure
BCP20743 SU 4312 5812-07-7
Potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 values are 0.8 and 19.4 μM respectively). Selective over EGFR and c-Src tyrosine kinases.
DCC-2618 Chemical Structure
BCP29218 DCC-2618 1442472-39-0
DCC-2618 is a pan-KIT and PDGFRA inhibitor, and has antitumor activity.
SIM010603 Chemical Structure
BCP25213 SIM010603 1032265-67-0
SIM010603 is a structurally novel, oral, multi-targeted receptor tyrosine kinase inhibitor.
TG 100801 Hydrochloride Chemical Structure
BCP25254 TG 100801 Hydrochloride 1018069-81-2
TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
Sitravatinib Chemical Structure
BCP29099 Sitravatinib 1123837-84-2
Sitravatinib (MGCD516,MG-516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl.
ABT-348 Chemical Structure
BCP07256 ABT-348 1227939-82-3
ABT-348, is a novel potent and orally bioavailable inhibitor of the Aurora kinases as well as the VEGF and PDGF families of receptor tyrosine kinases and is currently in Phase I clinical trials.
SKLB610 Chemical Structure
BCP28112 SKLB610 1125780-41-7
SKLB610 is a VEGFR inhibitor with potent anti-tumor activity.
TG100801 Chemical Structure
BCP02570 TG100801 867331-82-6
TG 100801 is currently in a clinical trial as a first in class, VEGFr2 targeting, topically applied compound for the treatment of AMD.
123下一页末页共 62 条记录 1 / 7 页